Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • ABSTRACT:Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive disease caused by mutations in the TTR gene leading to multisystem organ dysfunction. Pathogenic TTR aggregation, misfolding, and fibrillization lead to deposition of amyloid in multiple body organs and frequently involve the peripheral nerve system and the heart. Common neurologic manifestations include: sensorimotor polyneuropathy (PN), autonomic neuropathy, small-fiber PN, and carpal tunnel syndrome. Many patients have significant progression due to diagnostic delays as hATTR PN is not considered within the differential diagnosis. Recently, two effective novel disease-modifying therapies, inotersen and patisiran, were approved by Health Canada for the treatment of hATTR PN. Early diagnosis is crucial for the timely introduction of these disease-modifying treatments that reduce impairments, improve quality of life, and extend survival. In this guideline, we aim to improve awareness and outcomes of hATTR PN by making recommendations directed to the diagnosis, monitoring, and treatment in Canada.


  • Alcantara, Monica
  • Mezei, Michelle M
  • Baker, Steven
  • Breiner, Ari
  • Dhawan, Priya
  • Fiander, Amanda
  • Fine, Nowell M
  • Hahn, Christopher
  • Katzberg, Hans D
  • Khayambashi, Shahin
  • Massie, Rami
  • Matte, Genevieve
  • Putko, Brendan
  • Siddiqi, Zaeem
  • Delgado, Diego
  • Bril, Vera

publication date

  • January 2022